Full Press Release Details
Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
ROCKVILLE, Md., September 20, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company s management will present an overview and Company update as well as host investor meetings, at the 2018 Cantor Fitzgerald Global Healthcare Conference.
Date: Wednesday, October 3, 2018
Place: InterContinental New York Barclays Hotel, New York City
Investors interested in arranging a meeting with the Company s management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investors Section on the Company s website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company s website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com